Kaletra

Lopinavir/ritonavir, the active ingredient in Kaletra, is a protease inhibitor presented as a tablet for oral use. It is indicated for the treatment of HIV‑1 infection in both adult and pediatric patients, helping to suppress viral replication and improve immune function. The combination leverages ritonavir's pharmacokinetic boosting to maintain therapeutic lopinavir concentrations.

GNH USA supplies Kaletra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured antiretroviral medicines for health‑care systems across multiple regions and supporting treatment programs.

Kaletra is used in antiretroviral therapy targeting HIV‑1 infection.

- HIV‑1 infection in adults: reduces viral load and slows disease progression. - HIV‑1 infection in children: improves immune status and reduces opportunistic infections. - Treatment‑experienced HIV‑1 infection: provides an alternative regimen when resistance to other agents develops.

Kaletra may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools. - Nausea: feeling of sickness. - Headache: mild to moderate head pain. - Elevated triglycerides: increase in blood lipid levels.

Serious or Rare Side Effects: - Severe hepatotoxicity: liver enzyme elevations or hepatitis. - Pancreatitis: inflammation of the pancreas with abdominal pain. - QT interval prolongation: potential cardiac rhythm disturbance.

When prescribing Kaletra, clinicians should consider several precautionary measures to ensure safe use.

- Baseline liver function: assess hepatic enzymes before initiating therapy. - Drug resistance monitoring: perform viral load testing regularly to detect treatment failure. - Concomitant medications: review for potential CYP3A4 interactions. - Pregnancy and breastfeeding: evaluate risks versus benefits as safety data are limited. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture.

Kaletra interacts with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): markedly reduce lopinavir levels, risking therapeutic failure. - HIV protease inhibitors with overlapping toxicity (e.g., atazanavir): increase risk of hepatotoxicity. - Drugs that prolong QT interval (e.g., amiodarone): may exacerbate cardiac risk.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates with narrow therapeutic index (e.g., warfarin, certain statins): may require dose adjustment. - Oral contraceptives: efficacy may be reduced, consider alternative contraception.